Prothena Corp Public Ltd Co

PRTA

Pharmaceutical Preparations

Mkt Cap

$1.075B

PE

-6.24

Debt

Cash

$548.7M

EV

FCF

Market Cap

$1.075B

P/E Ratio

-6.24

Debt

Cash

$548.7M

EV

FCF

Charts data: {"Earnings":[{"time":"2014-12-30","value":-7150000},{"time":"2015-12-30","value":-80612000},{"time":"2016-12-30","value":-160108000},{"time":"2017-12-30","value":-153237000},{"time":"2018-12-30","value":-155645000},{"time":"2019-12-30","value":-77677000},{"time":"2020-12-30","value":-111144000},{"time":"2021-12-30","value":66975000},{"time":"2022-12-30","value":-116949000},{"time":"2023-12-30","value":-147028000}],"Sales":[{"time":"2014-12-30","value":50854000},{"time":"2015-12-30","value":1607000},{"time":"2016-12-30","value":1055000},{"time":"2017-12-30","value":27519000},{"time":"2018-12-30","value":955000},{"time":"2019-12-30","value":814000},{"time":"2020-12-30","value":853000},{"time":"2021-12-30","value":200577000},{"time":"2022-12-30","value":53905000},{"time":"2023-12-30","value":91370000}],"Net Margins":[{"time":"2014-12-30","value":-0.14059857631651393},{"time":"2015-12-30","value":-50.16303671437461},{"time":"2016-12-30","value":-151.7611374407583},{"time":"2017-12-30","value":-5.568407282241361},{"time":"2018-12-30","value":-162.97905759162305},{"time":"2019-12-30","value":-95.42628992628993},{"time":"2020-12-30","value":-130.29777256740914},{"time":"2021-12-30","value":0.33391166484691664},{"time":"2022-12-30","value":-2.1695390038029867},{"time":"2023-12-30","value":-1.6091496114698478}],"Assets":[{"time":"2014-12-30","value":304116000},{"time":"2015-12-30","value":385236000},{"time":"2016-12-30","value":459976000},{"time":"2017-12-30","value":496329000},{"time":"2018-12-30","value":498796000},{"time":"2019-12-30","value":419268000},{"time":"2020-12-30","value":332975000},{"time":"2021-12-30","value":609366000},{"time":"2022-12-30","value":758035000},{"time":"2023-12-30","value":696382000}],"Stockholders Equity":[{"time":"2014-12-30","value":289889000},{"time":"2015-12-30","value":360669000},{"time":"2016-12-30","value":365403000},{"time":"2017-12-30","value":407189000},{"time":"2018-12-30","value":322998000},{"time":"2019-12-30","value":272921000},{"time":"2020-12-30","value":184006000},{"time":"2021-12-30","value":466042000},{"time":"2022-12-30","value":622042000},{"time":"2023-12-30","value":561365000}],"ROE":[{"time":"2014-12-30","value":-0.024664613007047524},{"time":"2015-12-30","value":-0.22350687195184504},{"time":"2016-12-30","value":-0.43816826900709627},{"time":"2017-12-30","value":-0.3763289283354904},{"time":"2018-12-30","value":-0.4818760487681038},{"time":"2019-12-30","value":-0.2846134962131899},{"time":"2020-12-30","value":-0.604023781833201},{"time":"2021-12-30","value":0.14371022354208418},{"time":"2022-12-30","value":-0.18800820523373019},{"time":"2023-12-30","value":-0.2619115904981607}],"ROA":[{"time":"2014-12-30","value":-0.020844020044982835},{"time":"2015-12-30","value":-0.20743388468367444},{"time":"2016-12-30","value":-0.34559194392750925},{"time":"2017-12-30","value":-0.31280461145731964},{"time":"2018-12-30","value":-0.31298366466451216},{"time":"2019-12-30","value":-0.1843641775666161},{"time":"2020-12-30","value":-0.33464073879420375},{"time":"2021-12-30","value":0.11811456497408782},{"time":"2022-12-30","value":-0.16569815377917907},{"time":"2023-12-30","value":-0.23044823099965248}]}

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21
10-Q
3/31/21
10-K
12/31/20
10-Q
9/30/20
10-Q
6/30/20
10-Q
3/31/20
10-K
12/31/19
10-Q
9/30/19
10-Q
6/30/19
10-Q
3/31/19
10-K
12/31/18
10-Q
9/30/18
10-Q
6/30/18
10-Q
3/31/18
10-K
12/31/17

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -5.7%

Earnings Stability -65%

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Over time the ROA has been increasing indicating a higher marginal ROA with respect to the calculated one, giving a good sign for continued growth.

Years	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-5K%	-15K%	-560%	-16K%	-9.5K%	-13K%	33%	-220%	-160%	-190%
ROA	-21%	-35%	-31%	-31%	-18%	-33%	12%	-17%	-23%	-30%
ROE	-22%	-44%	-38%	-48%	-28%	-60%	14%	-19%	-26%	-34%

What is the average Net Margin?

The average Net Margin over the past 5 years is -6.54K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is +3.48K%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -18.5%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +2.63%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -27.95%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +6.11%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Data are missing

Years	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-	-	-	-	-	-	-	-	-
Debt Equity	-	-	-	-	-	-	-	-	-	-
MIN
Graham Stability	-	-	-	-	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2016	12-2018	12-2020	12-2022	Trend
Revenue	89%	150%	370%	70%	710%
Net Income	-	-	-	-	-
Stockholders Equity	6.3%	12%	45%	-9.8%	3.9%
FCF	-	-	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +148.98%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is +707.7%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -1.13%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +11.69%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +3.86%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.